Jpmorgan Chase & CO Enlivex Therapeutics Ltd. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,564 shares of ENLV stock, worth $2,692. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,564
Previous 1,814
41.35%
Holding current value
$2,692
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ENLV
# of Institutions
29Shares Held
3.43MCall Options Held
11.8KPut Options Held
9.1K-
Armistice Capital, LLC New York, NY2.21MShares$2.32 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny634KShares$665,5390.0% of portfolio
-
Morgan Stanley New York, NY270KShares$283,1370.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny159KShares$166,9410.0% of portfolio
-
Sigma Investment Counselors Inc28KShares$29,4000.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $19.3M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...